GSK Aug 2024 46.000 call
| Previous close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 46.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.4500 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ReutersGSK raises profit forecast, says sales growth to slow in H2
CEO Emma Walmsley's strategy has focussed on vaccines and infectious diseases and a shift in its HIV focus to long-acting treatment and prevention therapies. It expects a rise in 2024 sales in the upper end of its 5% to 7% forecast range. It also attributed its increased forecast to a successful royalty dispute appeal for ovary cancer drug Zejula in the first quarter.
Fool.co.ukI’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it
Harvey Jones has surprised himself by living up to Warren Buffett's most important investment rule. But is his success down to luck or judgement? The post I’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it appeared first on The Motley Fool UK.
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
